Piper Jaffray Starts GlaxoSmithKline (GSK) at Overweight
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Piper Jaffray initiated coverage on GlaxoSmithKline (NYSE: GSK) with an Overweight rating.
Shares of GlaxoSmithKline closed at $43.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD
- UPDATE: Goldman Sachs Starts Catalent (CTLT) at Neutral
- GlaxoSmithKline (GSK) Announces Filing Regulatory Submission with EMA for FF/UMEC/VI as COPD Treatment